Diagnosing a Personalized Partnership

Abbott Labs (NYSE: ABT  ) and GlaxoSmithKline (NYSE: GSK  ) each has something the other needs. Sounds like a good opportunity for a partnership.

Glaxo is developing a cancer vaccine that targets MAGE-A3, a marker that is presented on the surface of some, but not all, tumor cells. The vaccine -- aptly named MAGE-A3 ASCI, for Antigen Specific Cancer Immunotherapy -- only works if the tumor presents MAGE-A3.Currently, this is in a phase 3 trial for lung cancer.

Enter Abbott, which has an instrument -- non-aptly named the m2000 -- that can detect DNA sequences through PCR. The two announced yesterday that they'll develop a DNA test so that patients' tumors can be screened and only those presenting the MAGE-A3 marker will be given the drug. In other words, targeted therapy.

It's a bit of a risk for Abbott to develop a test for a treatment that's still in phase 3 trials, but it could pay off handsomely if MAGE-A3 ASCI turns out to work. Not only will Abbott be able to earn revenue on the tests it'll sell -- assuming the diagnostic test gets past the Food and Drug Administration -- but expanding into cancer diagnostics might also help the company place more m2000 instruments. The machine is currently used mostly for detecting or confirming infectious diseases.

Of course this isn't the first drug-diagnostic test partnership. Dako and Genentech set up a collaboration to develop a HER2 diagnostic test for using Herceptin to treat breast cancer back in 1998, but the number of drugs requiring personalized tests does seem to be growing. For instance, Life Technologies (Nasdaq: LIFE  ) and others have a test for a mutation in K-ras which affects whether Amgen's (Nasdaq: AMGN  ) Vectibix or Bristol-Myers Squibb's (NYSE: BMY  ) and Eli Lilly's (NYSE: LLY  ) Erbitux will work.

Sorry Glaxo, but I think diagnostic-test makers like Abbott, Life Technologies, and Myriad Genetics (Nasdaq: MYGN  ) are a better play on the growth in personalized medicine than the drug developers. The lower development costs and likely higher success rates make them a good choice, especially for risk-adverse investors.

Diagnose your portfolio with this additional Foolishness:

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 940747, ~/Articles/ArticleHandler.aspx, 10/30/2014 12:03:03 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 17,121.04 146.73 0.86%
S&P 500 1,986.01 3.71 0.19%
NASD 4,542.90 -6.33 -0.14%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/30/2014 11:46 AM
ABT $43.16 Up +0.42 +0.98%
Abbott Laboratorie… CAPS Rating: *****
GSK $45.03 Down -0.05 -0.11%
GlaxoSmithKline CAPS Rating: ****
AMGN $159.81 Up +0.93 +0.59%
Amgen, Inc. CAPS Rating: ****
BMY $58.63 Up +4.47 +8.24%
Bristol-Myers Squi… CAPS Rating: ****
LIFE.DL $0.00 Down +0.00 +0.00%
Life Technologies… CAPS Rating: ***
LLY $66.60 Up +1.11 +1.69%
Eli Lilly & Co. CAPS Rating: ****
MYGN $37.93 Down -0.07 -0.18%
Myriad Genetics CAPS Rating: ***

Advertisement